MTAP and glioblastoma: To investigate the role of purine supply in maintaining stemness, we employed naturally MTAP-deficient patient-derived GBM cell lines (GBM 12-0160 and GBM 12-0106), which were cultured in neural stem cell (NSC) medium to maintain their BTIC properties and were previously shown to be susceptible to ALA treatment [12].